tradingkey.logo

tradingkey.logo
怜玢


Scinai Immunotherapeutics Ltd

SCNI
りォッチリストに远加
1.910USD
+0.220+13.02%
終倀 09-22 16:00ET
1.29M時䟡総額
損倱額盎近12ヶ月PER

Scinai Immunotherapeutics Ltdに぀いお 䌁業名

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Scinai Immunotherapeutics Ltd プロフィヌル


䌁業コヌドSCNI
䌚瀟名Scinai Immunotherapeutics Ltd
䞊堎日Jun 07, 2007
最高経営責任者「CEO」Reichman (Amir)
埓業員数31
蚌刞皮類Depository Receipt
決算期末Jun 07
本瀟所圚地Jerusalem Biopark, 2Nd Floor
郜垂JERUSALEM
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Israel
郵䟿番号00000
電話番号97289302529
りェブサむトhttps://www.scinai.com/
䌁業コヌドSCNI
䞊堎日Jun 07, 2007
最高経営責任者「CEO」Reichman (Amir)

Scinai Immunotherapeutics Ltdの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Mark S. Germain
Mr. Mark S. Germain
Chairman of the Board
Chairman of the Board
120.00M
--
Mr. Mark S. Germain
Mr. Mark S. Germain
Chairman of the Board
Chairman of the Board
120.00M
--
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
1.95K
+58.59%
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
1.95K
+58.59%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
487.00
+73.92%
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
487.00
+73.92%
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
118.00
+76.27%
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
118.00
+76.27%
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Mark S. Germain
Mr. Mark S. Germain
Chairman of the Board
Chairman of the Board
120.00M
--
Mr. Mark S. Germain
Mr. Mark S. Germain
Chairman of the Board
Chairman of the Board
120.00M
--
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
1.95K
+58.59%
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
1.95K
+58.59%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--

よくある質問

Scinai Immunotherapeutics Ltdの䞊䜍5名の株䞻は誰ですか


Scinai Immunotherapeutics Ltdの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Mark S. Germain

Scinai Immunotherapeutics LtdSCNIの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Scinai Immunotherapeutics Ltdの株匏を保有しおいる機関は23瀟あり、保有株匏の総垂堎䟡倀は玄179.71Kで、党䜓の5.08%を占めおいたす。2025Q4ず比范しお、機関の持ち株は33890.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。